Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sanara MedTech Inc. filings on SEC EDGAR ↗
Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.
Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.
Sanara MedTech Inc. sold all assets of its wholly owned subsidiary, Tissue Health Plus, LLC (THP), to an unrelated third party. The transaction included THP's business software products and intellectual property for approximately $2.0 million plus certain earnout rights.